SIGA TECHNOLOGIES INC
SIGANasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $94.6M | $138.7M | $139.9M | $110.8M | $133.7M | $125.0M |
| Operating income | $23.7M | $70.0M | $83.6M | $42.7M | $89.1M | $84.5M |
| Net income | $23.3M | $59.2M | $68.1M | $33.9M | $69.5M | $56.3M |
| Total assets | $219.5M | $244.3M | $254.4M | $195.0M | $214.7M | $149.8M |
| Total liabilities | $20.6M | $28.5M | $57.5M | $24.9M | $40.4M | $20.0M |
| Equity | $198.8M | $215.8M | $196.9M | $170.2M | $174.3M | $129.8M |
| EPS (diluted) | $0.32 | $0.82 | $0.95 | $0.46 | $0.91 | $0.71 |
| Shares out. | 71.4M | 71.1M | 72.2M | 73.0M | 76.7M | 81.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 25.1%
- Net margin
- 24.6%
- Return on equity
- 11.7%
- Return on assets
- 10.6%
- Return on capital (ROCE)
- 11.8%
- Liabilities / assets
- 9.4%
- Debt / equity
- 0.10×
- Book value / share
- $2.78
- Revenue growth (YoY)
- −31.8%
- Net income growth (YoY)
- −60.7%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 16.02safe
- Accruals / assets
- −9.2%clean
- Beneish M-Score
- -4.03normal
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 5 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Revenue declined year-over-year
- Operating margin is positive
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 13, 2013
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
FDA-approved drugs
openFDA · most recent- TPOXXMay 18, 2022
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Blackrock, Inc.Passive (13G)Apr 25, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Miller Larry R.Officer — General Counsel | Mar 25, 2026 | Option exercise | 6,920 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 3.3M | 6.1 | -0.7% |
| Apr 30, 2026 | 3.3M | 8.2 | +3.1% |
| Apr 15, 2026 | 3.2M | 3.6 | -7.0% |
| Mar 31, 2026 | 3.5M | 4.1 | +10.6% |
| Mar 13, 2026 | 3.1M | 4.3 | -6.7% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 7, 2026
- Other material eventMar 26, 2026
- Results of operationsMar 10, 2026
- Results of operationsNov 6, 2025
- Results of operationsAug 5, 2025
- Amended charter or bylaws · Shareholder voteJun 12, 2025
- Results of operationsMay 8, 2025
- Other material eventApr 8, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.